In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
|Videos|August 22, 2014
Toxicity Profile of Panobinostat as seen in the PANORAMA Trial
Author(s)Andrzej Jakubowiak, MD, PhD
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.
Advertisement
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.
Clinical Pearls:
- In the PANORAMA trial, there was a higher proportion of GI toxicities in the panobinistat arm compared to the placebo arm.
- A higher rate of thrombocytopenia and other hematological toxicities were also seen in the panobinostat arm.
- However, all of the toxicities were mostly manageable and did not impact the outcome of the trial.
- More details are needed to get a better understanding of the toxicity profile of this combination in this setting.
Advertisement
Related to this article
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Frontline CAR T and Bispecific Antibodies Are the Next Frontier in Myeloma
5